News

New approach resets MS
Enlarge image

ResearchAustriaGermanySwitzerland

New approach resets MS

06.06.2013 - An international research team has found a way to calm the autoimmune reaction that leads to myelin destruction in Multiple Sclerosis patients.

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and reduced patients' immune system reactivity to myelin by 50 to 75 percent. In 9 patients, the researchers from Hamburg, Vienna, Zürich, and Chicago succeeded to reduce the autoimme reaction against myelin, which surrounds neurons like an insulator. They did so by coupling 7 myelin antigens thought to induce MS to the patients’ white blood cells ex vivo, which induced immune tolerance after reinjection in their bloodstream. Most of the patients who received high doses of the antigen-coupled blood cells did not show any new brain lesions or symptomatic relapses up to the end of the study’s six month follow-up period (Science Translat. Medicine, 5 May, 2013).

"The therapy stops autoimmune responses that are already activated and prevents the activation of new autoimmune cells," said co-author Stephen Miller from Northwestern University Feinberg School of Medicine. "Our approach leaves the function of the normal immune system intact. That's the holy grail." According to lead author Andreas Lutterotti from Innsbruck Medical University/Medical Center Hamburg-Eppendorf, the dead lymphocytes carrying the myelin antigens are filtered out of the blood in the spleen. During this process, immune cells start to recognise the myelin antigens as harmless and immune tolerance quickly develops. They confirmed this in patients by immune assays.

Although the patient numbers are small in this first-in-human study, the safety, feasibility, and early results suggest that this approach may provide a promising avenue for future trials. Unlike current immunosuppressive drugs for MS, the new approach does not compromise the immune system’s infection-fighting abilities. The process mimics a natural process by which millions of red and white blood cells, which normally die each day, are cleared from the bloodstream without alerting the immune system.  

The human safety study sets the stage for a phase 2 trial to see if the new treatment can prevent the progression of MS in humans. Scientists are currently trying to raise $1.5 million to launch the trial, which has already been approved in Switzerland. The new approach may be useful for treating not only MS but also a host of other autoimmune and allergic diseases simply by switching the antigens attached to the cells.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/new-approach-resets-ms.html

BusinessSwitzerland

03.07.2015 Biotech giant Biogen is investing CHF 1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, the new plant will create up to 400 jobs.

Personalised MedicineNetherlandsBelgiumSpain

02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE (D)10.45 EUR7.51%
  • WILEX (D)3.65 EUR5.49%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • 4SC (D)4.59 EUR-6.33%
  • BAVARIAN NORDIC (D)41.82 EUR-6.28%
  • BIOFRONTERA (D)2.06 EUR-5.50%

TOP

  • DBV Technologies (F)52.75 EUR22.8%
  • THERAMETRICS (CH)0.07 CHF16.7%
  • MEDIGENE (D)10.45 EUR16.6%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NORDIC NANOVECTOR (N)25.20 NOK-26.5%
  • TRANSGENE (F)3.68 EUR-26.4%

TOP

  • 4SC (D)4.59 EUR345.6%
  • ADOCIA (F)65.40 EUR336.0%
  • WILEX (D)3.65 EUR319.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)8.85 SEK-70.6%
  • NEOVACS (F)1.10 EUR-69.3%

No liability assumed, Date: 05.07.2015